Stanford University Genome Technology Center Advances Genetic Research and Development
News Feb 27, 2007
BioTrove, Inc. has announced that the Stanford University Genome Technology Center will advance multiple research projects through the use of the BioTrove OpenArray™ technology platform.
Researchers in the Stanford Genome Technology lab, led by Professor Ronald Davis, Director, anticipate applications in single nucleotide polymorphism (SNP) genotyping, real-time quantitative polymerase chain reaction (PCR)-based tests, and the development of uses for the OpenArray system.
“One of the challenges facing academic research centers today is access to high-accuracy, cost-sensible technology that enables our students and professors to bring their projects to life,” said Ronald Davis.
“By increasing the number of reactions analyzed at one time by as much as ten-fold, and with the flexibility to use its technology in multiple applications, the OpenArray platform enables faster, more cost-effective analysis of biologic samples. We also look forward to exploring new ways to use the OpenArray plates in our research,” he added.
According to BioTrove, with OpenArray plates and the OpenArray NT Imager, researchers can generate up to 100,000 SNP genotypes per day, without the need for expensive robotics. With the OpenArray plates and NT Cycler system, researchers can generate as many as 9,216 real time PCR data points at one time.
“By engaging important biological questions with breakthrough technology, Stanford Genome Technology Center researchers continue to innovate and lead the way in many areas of research,” said Albert Luderer, Ph.D., president and CEO, BioTrove.
“As a company committed to advancing research that improves public health and quality-of-life, BioTrove is excited to enable this work,” Luderer continued.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.